ThermoFisher (TMO) Offering Possible 21.21% Return Over the Next 14 Calendar Days

ThermoFisher's most recent trend suggests a bearish bias. One trading opportunity on ThermoFisher is a Bear Call Spread using a strike $290.00 short call and a strike $310.00 long call offers a potential 21.21% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $290.00 by expiration. The full premium credit of $3.50 would be kept by the premium seller. The risk of $16.50 would be incurred if the stock rose above the $310.00 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for ThermoFisher is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for ThermoFisher is bearish.

The RSI indicator is at 47.54 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for ThermoFisher

CORRECTED-Becton Dickinson, BioMedomics launch test to detect past, current coronavirus exposure
Wed, 01 Apr 2020 17:31:19 +0000
Becton Dickinson and Co and diagnostics company BioMedomics on Tuesday said they will launch a diagnostic test that can detect current or past exposure to the coronavirus within minutes, and can be used in doctors' offices, as well as other settings. The test is the latest to join an arsenal of diagnostic tools for the coronavirus that can be used in community health settings such as doctors' offices and urgent care clinics. “This is a simple blood test that can be done at the point of care without the need to involve a large laboratory,” David Hickey, president of Becton Dickinson's diagnostics division, told Reuters in a phone interview.

Healthcare ETFs Gain on Rising Demand for COVID-19 Tests
Tue, 31 Mar 2020 19:26:36 +0000
A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.

Investors Clamor for Credit With New Deal Demand Off the Charts
Mon, 30 Mar 2020 21:21:43 +0000
(Bloomberg) — Investors are meeting a flood of corporate debt issuance with even greater demand, a strong sign for risk appetite as issuers continue to bring new deals.YUM! Brands Inc., brought the first U.S. high-yield offering in nearly a month, boosted the size of its deal to $600 million from $500 million amid $3 billion of orders. Oracle Corp., which was downgraded by two credit raters after announcing a deal Monday, had amassed more than $50 billion in orders for what became a $20 billion offering, according to people with knowledge of the matter.Credit markets are showing signs of thawing, as strong reception of record investment-grade issuance has trickled into the high-yield market. While market access was initially limited to only top-notch firms like Exxon Mobil Corp. and PepsiCo Inc. just two weeks ago, investors have since gotten more comfortable with riskier names, and massive demand has cut down borrowing costs.Last week, U.S. companies borrowed a record $109 billion, met with $550 billion of demand, in what one dealer called a “food fight” for new bonds. It was a similar story in Europe, where investors placed more than 310 billion euros ($340 billion) of orders for about 75 billion euros of bonds. Asia’s dollar bond market, however, hasn’t had any issuance for several weeks.“As corporates should remain keen on retaining liquidity to weather the growing pain of lockdowns, we expect issuance windows to continue to attract issuers,” Commerzbank strategists said in a note to clients this morning.Investment-grade issuers marketed massive deals. Oracle was in the market for the first time since 2017 with a $20 billion six-part offering, with maturities ranging from five to 40 years. AB InBev’s 4.5 billion euro sale included bonds due in seven, 12 and 20 years.U.S.YUM! Brands sold the first junk bond sale since March 4, one of the most positive signs of the recovery in credit to date. The investment-grade market continues to be active, with 12 deals set to price a combined $37.175 billion.Sysco also sold a jumbo transaction with maturities ranging from five to 30 years. It’s a quick return for the company, which last sold bonds on Feb. 11Oracle’s bonds tightened 40 bps from initial talk to pricing as order books swelledFor deal updates, click here for the New Issue MonitorAirlines worldwide raised more than $17 billion in bank loans in March to shore up finances as the coronavirus grounds flights, with U.S. carriers like Delta the most activeEuropeSeven deals combined to price 10.8 billion euros, putting Europe’s primary market on a path to post 500 billion euros of quarterly sales for the first time.AB InBev, Thermo Fisher Scientific Inc. and Volkswagen AG led the calendar with multi-tranche offeringsGoldman Sachs says it’s too early to decisively say market’s have “turned the corner,” while JPMorgan says the worst has passedEuro IG company bond spreads at 241 basis points have eased slightly after reaching the highest since 2012, according to a Bloomberg Barclays index; current levels are about 35bps too wide as the market is “not properly discounting” ECB corporate bond purchases, according to ABN Amro strategistsCompanies are also heading to the loan market to shore up financial buffers, with Airbus and Daimler potentially closing at least 25 billion euros ($28 billion) of combined new loans within weeksAsiaThe Markit iTraxx Asia ex-Japan index of credit-default swaps increased about 8 basis points to around 142, according to traders; the gauge tumbled 49 basis points last week, its steepest fall on a percentage basis since 2009, according to CMA dataSpreads on Asia investment-grade dollar bonds were 5-10 basis points wider this morning, according to traders, putting them on track to widen for the first day in five; liquidity is very thin, according to one of the tradersGlobal credit is a “buyers’ market right now” for investors holding cash, according to portfolio manager Raymond Lee at Kapstream Capital. “Even high-quality, high-rated investment-grade names are trading very wide based on historicals and look like good investments”A global economic slowdown caused by virus containment steps “will trigger a default cycle in credit worldwide,” said Paul Lukaszewski, head of corporate debt for Asia and Australia at Aberdeen Standard Investments“The question for investors to assess is how severe this cycle will be compared to what is priced in,” he said, adding that the wide credit spread levels last week had reached the peaks of all prior downturns this century with the exception of the global financial crisisLocal currency markets in Asia have also been hit; the latest sign of that was in Korea, where yields have jumped:For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Thermo Fisher Scientific Inc. — Moody's assigns Baa1 to Thermo Fisher Scientific Inc.'s new senior unsecured European notes
Mon, 30 Mar 2020 21:06:12 +0000
Moody's Investors Service (Moody's) assigned a Baa1 rating to Thermo Fisher Scientific Inc.'s (“Thermo Fisher”) new senior unsecured European notes. There is no change to any of Thermo Fisher's existing Baa1 senior unsecured ratings or Prime-2 commercial paper ratings.

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
Mon, 30 Mar 2020 20:05:00 +0000
Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that it has priced an offering of €1.2 billion aggregate principal amount (the "Offering") of the following euro-denominated notes:

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.